Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022.
GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022.
Altimmune management will host a conference call at 8:30 am E.T. on March 15 to discuss financial results and provide a business update.
| Conference Call Information: | |
| Date: Time: Domestic Dial-in: International Dial-in: Conference ID: Webcast: | Tuesday, March 15 8:30 am Eastern Time (844) 615-6509 (918) 922-3148 4557398 https://edge.media-server.com/mmc/p/5www3cgz |
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor and Media Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
